Key facts
- Hemerion Therapeutics’s last known valuation is $26.2M (May 2025).
- It has raised $14.2M; the latest was Later Stage VC ($39.5M) in May 2025.
- Notable investors include Bpifrance, France 2030, Finorpa, Finovam Gestion, Fira Group — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Hemerion Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Hemerion Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Hemerion Therapeutics
Operator of a biotechnology platform intended to treat resistant tumors using proprietary photosensitizing molecules paired with advanced laser light technologies. The company offers a unique combination of photosensitizing compounds and controlled laser delivery, enabling oncologists focusing on hard-to-treat brain tumors to achieve highly precise tumor targeting.
- Sector
- Healthcare
- HQ
- Villeneuve-d'Ascq, France
- Founded
- 2020
- Employees
- 15
- Website
- hemerion.com/
- Ownership
- Privately Held (backing)
Hemerion Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Hemerion Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Hemerion Therapeutics in its N-PORT filings yet. We sweep new filings monthly.